论文部分内容阅读
目的：观察阿柔比星联合化疗对急性白血病的效果。方法：急性白血病２６例，其中急性淋巴细胞白血病（急淋）１０例，男性６例，女性４例，年龄２７±ｓ１０ａ。急性非淋巴细胞白血病（急非淋）１６例，男性１１例，女性５例，年龄３８±１２ａ。急淋用ＶＡＰ方案（长春新碱＋阿柔比星＋泼尼松）；急非淋用ＨＡＡ方案（三尖杉酯碱＋阿柔比星＋阿糖胞苷）。结果：急淋有效率为９０％；急非淋有效率为８１％。结论：用阿柔比星为主的ＶＡＰ和ＨＡＡ方案对急性白血病的疗效满意。
Objective: To observe the effect of aclarubicin combined with chemotherapy on acute leukemia. Methods: 26 cases of acute leukemia, including acute lymphoblastic leukemia (emergency lymph) in 10 cases, 6 males and 4 females, age 27 ± s10a. Acute non-lymphocytic leukemia (emergency non-lymphocytic) in 16 cases, 11 males and 5 females, age 38 ± 12a. Acute vaccination with VAP regimen (vincristine + arubicin + prednisone); acute non-leaching HAA regimen (harringtonine + arurubin + cytarabine). Results: The effective rate of acute leaching was 90%; the effective rate of acute non leaching was 81%. CONCLUSIONS: VAP and HAA regimens based on aclarubicin are satisfactory for acute leukemia.